Page last updated: 2024-10-30

metformin and Anorexia

metformin has been researched along with Anorexia in 6 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.

Research Excerpts

ExcerptRelevanceReference
"7%) stopped metformin therapy due to excessive anorexia."7.74Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008)
"Liraglutide provided better glycaemic control and greater body weight reduction than sitagliptin when administered as add-on to metformin."5.22Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. ( Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L, 2016)
"Metformin reduces body weight by decreasing food intake in humans and animals."3.83The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. ( Choi, SH; Jin, BY; Kim, DH; Kim, HJ; Oh, MJ; Shin, KH, 2016)
"7%) stopped metformin therapy due to excessive anorexia."3.74Treatment of white coat hypertension with metformin. ( Camci, C; Helvaci, MR; Sevinc, A; Yalcin, A, 2008)
"The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms controlling food intake."1.34A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia. ( Carvalheira, JB; de Souza, CT; Faria, MC; Morari, J; Pauli, JR; Ropelle, ER; Saad, MJ; Ueno, M; Velloso, LA; Zecchin, KG, 2007)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, HJ1
Jin, BY1
Oh, MJ1
Shin, KH1
Choi, SH1
Kim, DH1
Zang, L1
Liu, Y1
Geng, J1
Luo, Y1
Bian, F1
Lv, X1
Yang, J1
Liu, J1
Peng, Y1
Li, Y1
Sun, Y1
Bosch-Traberg, H1
Mu, Y1
Helvaci, MR1
Sevinc, A1
Camci, C1
Yalcin, A1
Wong, LL1
Wong, TC1
Ropelle, ER1
Pauli, JR1
Zecchin, KG1
Ueno, M1
de Souza, CT1
Morari, J1
Faria, MC1
Velloso, LA1
Saad, MJ1
Carvalheira, JB1
Linder, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINAâ„¢)[NCT02008682]Phase 4368 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 7-point Self-measured Plasma Glucose Profile

Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time. (NCT02008682)
Timeframe: Week 0, week 26

Interventionmmol/L (Mean)
Liraglutide-2.25
Sitagliptin-1.36

Change From Baseline in Fasting Plasma Glucose

Mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26

Interventionmmol/L (Mean)
Liraglutide-2.347
Sitagliptin-1.205

Change From Baseline in Glycosylated Haemoglobin (HbA1c)

Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT02008682)
Timeframe: Week 0, week 26

InterventionPercent (%) glycosylated haemoglobin (Mean)
Liraglutide-1.666
Sitagliptin-0.969

Number of Confirmed Hypoglycaemic Episodes

confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose < 3.1 mmol/L (NCT02008682)
Timeframe: Weeks 0-26

Interventionepisodes (Number)
Liraglutide2
Sitagliptin1

Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment

Interventionpercentage of subjects (Number)
Liraglutide76.5
Sitagliptin52.6

Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c <= 6.5% at Week 26 (NCT02008682)
Timeframe: After 26 weeks of treatment

Interventionpercentage of subjects (Number)
Liraglutide61.7
Sitagliptin26.3

Trials

1 trial available for metformin and Anorexia

ArticleYear
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; Chin

2016

Other Studies

5 other studies available for metformin and Anorexia

ArticleYear
The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period.
    Physiology & behavior, 2016, Feb-01, Volume: 154

    Topics: Analysis of Variance; Animals; Anorexia; Body Weight; Brain; Diet, High-Fat; Eating; Gene Expression

2016
Treatment of white coat hypertension with metformin.
    International heart journal, 2008, Volume: 49, Issue:6

    Topics: Adolescent; Adult; Aged; Anorexia; Appetite Depressants; Blood Glucose; Dyslipidemias; Female; Human

2008
Metformin induced anorexia and weight loss.
    Hawaii medical journal, 2003, Volume: 62, Issue:5

    Topics: Aged; Aged, 80 and over; Anorexia; Female; Humans; Hypoglycemic Agents; Metformin; Weight Loss

2003
A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia.
    Endocrinology, 2007, Volume: 148, Issue:11

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anorexia; Deoxyglucose; Drug Adm

2007
Clinical problem-solving: a square peg in a round hole.
    The New England journal of medicine, 1998, Jun-25, Volume: 338, Issue:26

    Topics: Anorexia; Humans; Hyperglycemia; Metformin

1998